<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Clofibrate</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00636</strong>&#160; (APRD00879)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A fibric acid derivative used in the treatment of hyperlipoproteinemia type <span class="caps">III</span> and severe hypertriglyceridemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00636/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00636/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00636.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00636.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00636.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00636.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00636.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00636">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>2-(4-Chlorophenoxy)-2-methylpropanoic acid ethyl ester</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>2-(p-Chlorophenoxy)-2-methylpropionic acid ethyl ester</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>alpha-(p-Chlorophenoxy)isobutyric acid, ethyl ester</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>alpha-p-Chlorophenoxyisobutyryl ethyl ester</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Clofibrato</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>INN</td></tr><tr><td>Clofibratum</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>INN</td></tr><tr><td>EPIB</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ethyl chlorophenoxyisobutyrate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ethyl clofibrate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Alufibrate</td><td>The Central</td></tr><tr><td>Atromid-S</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Binograc</td><td>Kotobuki Seiyaku</td></tr><tr><td>Clobrate</td><td>Johnson</td></tr><tr><td>Clofibrate</td><td>Banner</td></tr><tr><td>Hisunsero</td><td>Newai Chem</td></tr><tr><td>Koliva</td><td>Golden Horse</td></tr><tr><td>Myanlin</td><td>Sinton</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anticholesteremic-agents">Anticholesteremic Agents</a></li>
<li><a href="/mesh/hypolipidemic-agents">Hypolipidemic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>637-07-0</td></tr><tr><th>Weight</th><td>Average: 242.699<br>Monoisotopic: 242.070972053</td></tr><tr><th>Chemical Formula</th><td>C<sub>12</sub>H<sub>15</sub>ClO<sub>3</sub></td></tr><tr><th>InChI Key</th><td>KNHUKKLJHYUCFP-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">ethyl 2-(4-chlorophenoxy)-2-methylpropanoate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00636.gif?1265922771">show</a>(7.78 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenoxyacetic Acid Derivatives</td></tr><tr><th>Direct parent</th><td>Phenoxyacetic Acid Derivatives</td></tr><tr><th>Alternative parents</th><td>Phenol Ethers; Alkyl Aryl Ethers; Chlorobenzenes; Aryl Chlorides; Carboxylic Acid Esters; Enolates; Polyamines; Organochlorides</td></tr><tr><th>Substituents</th><td>phenol ether; alkyl aryl ether; chlorobenzene; aryl halide; aryl chloride; carboxylic acid ester; ether; enolate; carboxylic acid derivative; polyamine; organochloride; organohalogen</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenoxyacetic acid derivatives. These are compounds containing an anisole where the methane group is linked to an acetic acid or a derivative.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For Primary Dysbetalipoproteinemia (Type III hyperlipidemia) that does not respond adequately to diet. This helps control high cholesterol and high triglyceride levels. </td></tr><tr><th>Pharmacodynamics</th><td>Clofibrate is an antilipidemic agent similar to gemfibrozil. It acts to lower elevated serum lipids by reducing the very low-density lipoprotein fraction (S<sub>f</sub> 20-400) rich in triglycerides. Serum cholesterol may be decreased, particularly in those patients whose cholesterol elevation is due to the presence of IDL as a result of Type III hyperlipoproteinemia. Several investigators have observed in their studies that clofibrate may produce a decrease in cholesterol linoleate but an increase in palmitoleate and oleate, the latter being considered atherogenic in experimental animals. The significance of this finding is unknown at this time. Reduction of triglycerides in some patients treated with clofibrate or certain of its chemically and clinically similar analogs may be associated with an increase in LDL cholesterol. Increase in LDL cholesterol has been observed in patients whose cholesterol is initially normal. Animal studies suggest that clofibrate interrupts cholesterol biosynthesis prior to mevalonate formation.</td></tr><tr><th>Mechanism of action</th><td>Clofibrate increases the activity of extrahepatic lipoprotein lipase (LL), thereby increasing lipoprotein triglyceride lipolysis. Chylomicrons are degraded, VLDLs are converted to LDLs, and LDLs are converted to HDL. This is accompanied by a slight increase in secretion of lipids into the bile and ultimately the intestine. Clofibrate also inhibits the synthesis and increases the clearance of apolipoprotein B, a carrier molecule for VLDL. Also, as a fibrate, Clofibrate is an agonist of the PPAR-&#945; receptor[4] in muscle, liver, and other tissues. This agonism ultimately leads to modification in gene expression resulting in increased beta-oxidation, decreased triglyceride secretion, increased HDL, increased lipoprotein lipase activity.</td></tr><tr><th>Absorption</th><td>Completely but slowly absorbed from the intestine. Between 95% and 99% of an oral dose of clofibrate is excreted in the urine as free and conjugated clofibric acid; thus, the absorption of clofibrate is virtually complete.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Highly protein-bound (95% to 97%).</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic and gastrointestinal: rapid de-esterification occurs in the gastrointestinal tract and/or on first-pass metabolism to produce the active form, clofibric acid (chlorophenoxy isobutyric acid [CPIB]).</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>Half-life in normal volunteers averages 18 to 22 hours (range 14 to 35 hours) but can vary by up to 7 hours in the same subject at different times.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Oral, mouse: LD<sub>50</sub> = 1220 mg/kg; Oral, rabbit: LD<sub>50</sub> = 1370 mg/kg; Oral, rat: LD<sub>50</sub> = 940 mg/kg. No reported case of overdosage in humans.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9329</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.717</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.589</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7133</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8544</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8868</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8517</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6692</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9107</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8861</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.5832</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9132
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.5492
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9711
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.3806 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9891
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8735
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Wyeth ayerst laboratories</li>
<li>Banner pharmacaps inc</li>
<li>Sandoz inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Usl pharma inc</li>
<li>Watson laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.banpharm.com">Banner Pharmacaps Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li>Novopharm Ltd.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The fibrate increases the anticoagulant effect</td></tr><tr><td><a href="/drugs/DB00414">Acetohexamide</a></td><td>Clofibrate may increase the effect of sulfonylurea, acetohexamide.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The fibrate increases the anticoagulant effect</td></tr><tr><td><a href="/drugs/DB00672">Chlorpropamide</a></td><td>Clofibrate may increase the effect of sulfonylurea, chlorpropamide.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The fibrate increases the anticoagulant effect</td></tr><tr><td><a href="/drugs/DB01120">Gliclazide</a></td><td>Clofibrate may increase the effect of sulfonylurea, gliclazide.</td></tr><tr><td><a href="/drugs/DB01067">Glipizide</a></td><td>Clofibrate may increase the effect of sulfonylurea, glipizide.</td></tr><tr><td><a href="/drugs/DB01289">Glisoxepide</a></td><td>Clofibrate may increase the effect of sulfonylurea, glisoxepide.</td></tr><tr><td><a href="/drugs/DB01016">Glyburide</a></td><td>Clofibrate may increase the effect of sulfonylurea, glibenclamide.</td></tr><tr><td><a href="/drugs/DB01382">Glycodiazine</a></td><td>Clofibrate may increase the effect of sulfonylurea, glycodiazine.</td></tr><tr><td><a href="/drugs/DB01306">Insulin Aspart</a></td><td>Increases the effect of insulin</td></tr><tr><td><a href="/drugs/DB01307">Insulin Detemir</a></td><td>Increases the effect of insulin</td></tr><tr><td><a href="/drugs/DB01309">Insulin Glulisine</a></td><td>Increases the effect of insulin</td></tr><tr><td><a href="/drugs/DB00839">Tolazamide</a></td><td>Clofibrate may increase the effect of sulfonylurea, tolazamide.</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Clofibrate may increase the effect of sulfonylurea, tolbutamide.</td></tr><tr><td><a href="/drugs/DB01586">Ursodeoxycholic acid</a></td><td>The fibric acid derivative decreases the effect of ursodiol</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>The fibrate increases the anticoagulant effect</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take with food, since it may reduce gastric irritation.</li></ul></td></tr></tbody></table>